hepatitis
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
August 22, 2025Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …
First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment
June 19, 2024Research and Development Assembly Biosciences, Hepatology, clinical trial, hepatitis
Assembly Biosciences has announced that the first participant has been dosed in its phase 1b trial of ABI-4334, the company’s …
NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis
May 15, 2023Medical Communications NHS, NICE, Virology, hepatitis
The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta …
AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients
September 27, 2019Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma
The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …
AbbVie sue NHS over hepatitis C drug procurement
November 8, 2018Business Services AbbVie, NHS, britain, court, hep C, hepatitis, ruling
American pharma firm AbbVie are suing Britain’s NHS after claiming that the health service’s procurement of hepatitis C drugs breached …
Nine in 10 people unaware they have hepatitis
July 28, 2017Medical Communications, Research and Development Gilead, biotech, drugs, hepatitis, hepatitis C, pharma, pharmaceutical
The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with …
Gilead’s Sovaldi gets Indian patent; critics call it “major blow” to patient access
May 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing India, harm, hepatitis, patent, patient access, sovaldi
Gilead has been granted a patent for its hepatitis C drug, Sovaldi (sofosbuvir), in India which has sparked dismay among …
Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies
April 20, 2016Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir
Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …
AbbVie announces positive Phase III results in hepatitis C drug
April 14, 2016Manufacturing and Production, Research and Development AbbVie, hepatitis, phase III
AbbVie (NYSE: ABBV) has announced positive results from their Phase III evaluating the combination of Viekirax and Exviera, with or …
Medicines Patent Pool to include hep C and TB drugs
November 9, 2015Sales and Marketing Medicines Patent Pool, affordable drugs, hep C, hepatitis, hepatitis C, medicines access, tuberculosis
The Medicines Patent Pool has expanded to include a mandate to make treatments for hepatitis C and tuberculosis affordable and …
Gilead frustrated despite final NICE Sovaldi nod
February 25, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi
NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …
Janssen privy to new pricing scheme and see NICE nod
January 16, 2015Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir
Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …
NICE approves Sovaldi
January 16, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi
NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …
Abbvie Hep C drug gains FDA approval
December 22, 2014Sales and Marketing AbbVie, FDA, Gilead, Viekira Pak, dasabuvir, harvoni, hepatitis, hepatits C
Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …
J&J hepatitis C drug begins phase III trials
February 23, 2011Research and Development J&J, JJ, Johnson and Johnson, TMC435, Tibotec, hepatitis, hepatitis C
Johnson & Johnson has begun late stage trials of hepatitis C drug TMC435 as a first line treatment for the …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
